Human Microbiome Market

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

Report Code: BT 2711 May, 2023, by marketsandmarkets.com

The global human microbiome market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of the market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.

Attractive Opportunities in the human microbiome market

Human Microbiome Market

To know about the assumptions considered for the study, Request for Free Sample Report

Human Microbiome Market

Human Microbiome Market Dynamics

DRIVER: Collaborative efforts between microbiome industry and academia for microbiome research

The microbiome industry and academia have forged collaborative efforts to advance microbiome research. This partnership leverages the expertise and resources of both sectors to unravel the complex interactions between microbes and their hosts. Industry provides valuable funding, technological innovations, and access to large-scale datasets, while academia contributes cutting-edge research, scientific rigor, and diverse academic perspectives. By working together, they accelerate the discovery of novel insights into the microbiome's role in health and disease, paving the way for innovative therapies, diagnostics, and personalized medicine approaches. This collaborative approach fosters a synergistic relationship that benefits both scientific progress and the translation of microbiome research into real-world applications.

RESTRAINT: Adverse impact of complex regulatory policies on commercialization of microbiomes

Complex regulatory policies can have adverse impacts on the commercialization of microbiomes. The dynamic and rapidly evolving nature of microbiome research presents unique challenges in navigating regulatory frameworks. Lengthy approval processes, high costs, and stringent requirements can hinder the timely development and launch of microbiome-based products and therapies. These obstacles disproportionately affect small and medium-sized enterprises (SMEs) and startups, limiting their ability to compete with larger established companies. Moreover, inconsistent regulations across different regions or countries can create barriers to global market access, further impeding commercialization efforts. Streamlining and harmonizing regulatory policies, promoting clear guidelines, and fostering collaboration between regulatory agencies and industry stakeholders are essential to facilitate innovation and ensure the responsible and efficient commercialization of microbiome-based technologies.

OPPORTUNIY: Increased collaboration of key players and small innovative companies to work on new microbiome technologies

The increased collaboration between key players and small innovative companies in the field of microbiome technologies is driving transformative advancements. Key players, such as established industry leaders and research institutions, recognize the potential of microbiome-based solutions and actively seek partnerships with smaller, agile companies at the forefront of innovation. These collaborations bring together complementary expertise, resources, and networks, fostering a synergistic environment for the development and commercialization of novel microbiome technologies. By pooling their collective strengths, these partnerships accelerate research, enhance product development, and enable faster market entry. This collaborative approach not only spurs innovation but also ensures a diverse range of perspectives, driving the discovery of groundbreaking solutions that can positively impact human health and various industries, such as agriculture, pharmaceuticals, and consumer goods.

CHALLENGE: Slow patient adoption of microbiome-based therapies

There is a lack of awareness and understanding among the general public about the microbiome and its role in health. Many patients may be unfamiliar with the concept of microbial communities within their bodies and may be hesitant to try treatments that involve manipulating these communities. Moreover, the novelty and complexity of microbiome-based therapies may lead to skepticism and caution among patients, who may prefer more established or conventional treatment options. Additionally, the high cost of microbiome-based therapies and limited insurance coverage can pose financial barriers for patients, limiting their access and willingness to adopt these treatments. Overcoming these challenges requires comprehensive patient education, robust clinical evidence, affordable pricing, and expanded insurance coverage to build trust and encourage broader adoption of microbiome-based therapies.

Human Microbiome Market Ecosystem

Prominent companies in the market include well established, financially stable manufacturers of human microbiomes products. These companies have been operating in the market for several years and posees diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in this market include Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Human Microbiome Market Ecosystem

The drugs segment accounted for the largest share of the product segment in human microbiome market in 2023.

Based on products, the market is categorized into drugs, diagnostic tests, probiotics, prebiotics, and other products. In 2023, the drugs segment accounted for the largest share of the market. This segment’s large share can primarily be attributed to factors such as an increasing number of microbiome-based drugs in the pipeline and growing funding for drug development.

The Infectious diseases segment dominated the disease segment in human microbiome market in 2023.

Based on the disease, the segment is categorized into infectious diseases, gastrointestinal diseases, endocrine & metabolic disorders, cancer, and other diseases. In 2023, the infectious diseases segment dominated the technology segment with the highest revenue share. The large share of this segment is due to the increasing research in microbiome-based products and their use in treating infectious diseases.

North America was the largest market for human microbiome market in 2023.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The market is dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period. The established research infrastructure, technological advancements, demand for precision medicine, supportive regulatory environment, robust biotechnology and healthcare industry, and availability of funding and investment drive the growth of the market in North America. However, the high cost associated with certain human microbiomes, which can limit the adoption of these products for some customers, especially smaller research institutions or clinics with limited budgets are negatively impacting the market growth.

Human Microbiome Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Human Microbiome Market Report Scope

Report Metric 

Details 

Market Revenue in 2023

$0.3 billion

Projected Revenue by 2029

$1.7 billion

Revenue Rate

Poised to grow at a CAGR of 36.1%

Market Driver

Collaborative efforts between microbiome industry and academia for microbiome research

Market Opportunity

Increased collaboration of key players and small innovative companies to work on new microbiome technologies

This report categorizes the human microbiome market to forecast revenue and analyze trends in each of the following submarkets:

By product

  • Drugs
  • Diagnostic Tests
  • Probiotics
  • Prebiotics
  • Other Products

By Disease

  • Infectious Diseases
  • Gastrointestinal Diseases
  • Endocrine & Metabolic Disorders
  • Cancer
  • Other Diseases

By Application

  • Therapeutics
  • Diagnostics

By Type

  • Bacterial Consortia Transplantation (BCT)/Fecal Microbiota Transplantation (FMT)
  • Peptides
  • Live Biotherapeutic Products
  • Other Types

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • India
    • China
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World

Recent Developments

  • In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza’s Ibex campus in Visp, Switzerland.
  • In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.
  • In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 25)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY 
    1.6 RESEARCH LIMITATIONS 
    1.7 STAKEHOLDERS 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA 
          FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
          FIGURE 4 MARKET SIZE, 2023 (USD MILLION)
          FIGURE 5 MARKET: FINAL CAGR PROJECTIONS (2023−2029)
          FIGURE 6 MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.3 MARKET DATA ESTIMATION AND TRIANGULATION 
           2.3.1 DATA TRIANGULATION
                    FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 INDUSTRY INSIGHTS 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 MARKET: GLOBAL RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 38)
    FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
    FIGURE 9 MARKET, BY APPLICATION,  2023 VS. 2029 (USD MILLION)
    FIGURE 10 MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)
    FIGURE 11 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 41)
    4.1 HUMAN MICROBIOME MARKET OVERVIEW 
          FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
    4.2 NORTH AMERICA: MARKET,BY APPLICATION AND COUNTRY (2023) 
          FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
    4.3 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 
          FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 43)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
          TABLE 4 MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research
                    5.2.1.2 Surging demand for personalized medicine
                    5.2.1.3 Rising awareness about importance of human microbiome
           5.2.2 RESTRAINTS
                    5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies
                                TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT
           5.2.4 CHALLENGES
                    5.2.4.1 Slow patient adoption of microbiome-based therapies
                    5.2.4.2 Complexities involved in development of microbiome therapies
    5.3 TECHNOLOGY ANALYSIS 
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    5.5 SUPPLY AND VALUE CHAIN ANALYSIS 
           5.5.1 MARKET: SUPPLY CHAIN ANALYSIS
                    FIGURE 17 MARKET: SUPPLY CHAIN ANALYSIS
           5.5.2 VALUE CHAIN ANALYSIS OF MARKET
                    FIGURE 18 MARKET: VALUE CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 19 MARKET: ECOSYSTEM ANALYSIS
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 6 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF BUYERS
           5.7.4 BARGAINING POWER OF SUPPLIERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 REGULATORY ANALYSIS 
           5.8.1 FDA APPROVALS
           5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,  AND OTHER ORGANIZATIONS
    5.9 PRICING ANALYSIS 
          TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
           5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
    5.10 KEY CONFERENCES AND EVENTS IN 2023 
           5.10.1 HUMAN MICROBIOME CONFERENCES (2023)
                     TABLE 12 HUMAN MICROBIOME CONFERENCES (2023)
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 20 MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
           5.11.2 MARKET: BUYING CRITERIA
                     FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS
 
6 HUMAN MICROBIOME MARKET, BY APPLICATION (Page No. - 61)
    6.1 INTRODUCTION 
          TABLE 13 MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
    6.2 THERAPEUTICS 
           6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET
                    TABLE 14 MARKET FOR THERAPEUTICS, BY REGION,  2023–2029 (USD MILLION)
                    TABLE 15 NORTH AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 16 EUROPE: MARKET FOR THERAPEUTICS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 17 ASIA PACIFIC: MARKET FOR THERAPEUTICS, BY COUNTRY,  2023–2029 (USD MILLION)
    6.3 DIAGNOSTICS 
           6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
                    TABLE 18 MARKET FOR DIAGNOSTICS, BY REGION,  2023–2029 (USD MILLION)
                    TABLE 19 NORTH AMERICA: MARKET FOR DIAGNOSTICS,  BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 20 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY,  2023–2029 (USD MILLION)
 
7 HUMAN MICROBIOME MARKET, BY DISEASE (Page No. - 68)
    7.1 INTRODUCTION 
          TABLE 22 MARKET, BY DISEASE, 2023–2029 (USD MILLION)
    7.2 INFECTIOUS DISEASES 
           7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET
                    TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR  INFECTIOUS DISEASES
                    TABLE 24 MARKET FOR INFECTIOUS DISEASES, BY REGION,  2023–2029 (USD MILLION)
                    TABLE 25 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 26 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
    7.3 GASTROINTESTINAL DISEASES 
           7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET
                    TABLE 28 MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 29 NORTH AMERICA: MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 30 EUROPE: MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2023–2029 (USD MILLION)
    7.4 ENDOCRINE & METABOLIC DISORDERS 
           7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET
                    TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS
                    TABLE 33 MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 34 NORTH AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 35 EUROPE: MARKET FOR ENDOCRINE & METABOLIC DISORDERS,  BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
    7.5 CANCER 
           7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET
                    TABLE 37 MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 38 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 39 EUROPE: MARKET FOR CANCER, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY,  2023–2029 (USD MILLION)
    7.6 OTHER DISEASES 
          TABLE 41 MARKET FOR OTHER DISEASES, BY REGION,  2023–2029 (USD MILLION)
          TABLE 42 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
          TABLE 43 EUROPE: MARKET FOR OTHER DISEASES, BY COUNTRY,  2023–2029 (USD MILLION)
          TABLE 44 ASIA PACIFIC: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
 
8 HUMAN MICROBIOME MARKET, BY PRODUCT (Page No. - 80)
    8.1 INTRODUCTION 
          TABLE 45 MARKET, BY PRODUCT, 2023–2029 (USD MILLION))
    8.2 DRUGS 
           8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET
                    TABLE 46 MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 47 NORTH AMERICA: MARKET FOR DRUGS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 48 EUROPE: MARKET FOR DRUGS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 49 ASIA PACIFIC: MARKET FOR DRUGS, BY COUNTRY,  2023–2029 (USD MILLION)
    8.3 DIAGNOSTIC TESTS 
           8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET
                    TABLE 50 MARKET FOR DIAGNOSTIC TESTS, BY REGION,  2023–2029 (USD MILLION)
                    TABLE 51 NORTH AMERICA: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 52 EUROPE: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
    8.4 PROBIOTICS 
           8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY
                    TABLE 54 MARKET FOR PROBIOTICS, BY REGION,  2023–2029 (USD MILLION)
                    TABLE 55 NORTH AMERICA: MARKET FOR PROBIOTICS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 56 EUROPE: MARKET FOR PROBIOTICS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: MARKET FOR PROBIOTICS, BY COUNTRY,  2023–2029 (USD MILLION)
    8.5 PREBIOTICS 
           8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH
                    TABLE 58 MARKET FOR PREBIOTICS, BY REGION,  2023–2029 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR PREBIOTICS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR PREBIOTICS, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR PREBIOTICS, BY COUNTRY,  2023–2029 (USD MILLION)
    8.6 OTHER PRODUCTS 
          TABLE 62 MARKET FOR OTHER PRODUCTS, BY REGION,  2023–2029 (USD MILLION)
          TABLE 63 NORTH AMERICA: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
          TABLE 64 EUROPE: MARKET FOR OTHER PRODUCTS, BY COUNTRY,  2023–2029 (USD MILLION)
          TABLE 65 ASIA PACIFIC: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
 
9 HUMAN MICROBIOME MARKET, BY TYPE (Page No. - 92)
    9.1 INTRODUCTION 
          TABLE 66 MARKET, BY TYPE, 2023–2029 (USD MILLION)
    9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 
           9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH
                    TABLE 67 MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 68 NORTH AMERICA: MARKET FOR BCT/FMT, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 69 EUROPE: MARKET FOR BCT/FMT, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 70 ASIA PACIFIC: MARKET FOR BCT/FMT, BY COUNTRY,  2023–2029 (USD MILLION)
    9.3 PEPTIDES 
           9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET
                    TABLE 71 MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR PEPTIDES, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR PEPTIDES, BY COUNTRY,  2023–2029 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR PEPTIDES, BY COUNTRY,  2023–2029 (USD MILLION)
    9.4 LIVE BIOTHERAPEUTIC PRODUCTS 
           9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET
                    TABLE 75 MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 76 NORTH AMERICA: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 77 EUROPE: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS,  BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 78 ASIA PACIFIC: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS,  BY COUNTRY, 2023–2029 (USD MILLION)
    9.5 OTHER TYPES 
          TABLE 79 MARKET FOR OTHER TYPES, BY REGION,  2023–2029 (USD MILLION)
          TABLE 80 NORTH AMERICA: MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)
          TABLE 81 EUROPE: MARKET FOR OTHER TYPES, BY COUNTRY,  2023–2029 (USD MILLION)
          TABLE 82 ASIA PACIFIC: MARKET FOR OTHER TYPES, BY COUNTRY,  2023–2029 (USD MILLION)
 
10 HUMAN MICROBIOME MARKET, BY REGION (Page No. - 101)
     10.1 INTRODUCTION 
             FIGURE 22 MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)
             TABLE 83 MARKET, BY REGION, 2023–2029 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
             TABLE 84 NORTH AMERICA: MARKET, BY PRODUCT,  2023–2029 (USD MILLION)
             TABLE 85 NORTH AMERICA: MARKET, BY DISEASE,  2023–2029 (USD MILLION)
             TABLE 86 NORTH AMERICA: MARKET, BY APPLICATION,  2023–2029 (USD MILLION)
             TABLE 87 NORTH AMERICA: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Spike in research activities to drive market
                                      TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 89 US: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 90 US: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 91 US: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research
                                      TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 93 CANADA: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 94 CANADA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 95 CANADA: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
             TABLE 97 EUROPE: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
             TABLE 98 EUROPE: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
             TABLE 99 EUROPE: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Rapid increase in government funding to propel market
                                      TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 101 GERMANY: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 102 GERMANY: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 103 GERMANY: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Significant government investments in genomics research to propel growth
                                      TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 105 UK: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 106 UK: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 107 UK: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rise in microbiome sequencing startups to boost growth
                                      TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE
                                      TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 110 FRANCE: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 111 FRANCE: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 112 FRANCE: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.3.4 REST OF EUROPE
                        TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,  2023–2029 (USD MILLION)
                        TABLE 114 REST OF EUROPE: MARKET, BY DISEASE,  2023–2029 (USD MILLION)
                        TABLE 115 REST OF EUROPE: MARKET, BY APPLICATION,  2023–2029 (USD MILLION)
                        TABLE 116 REST OF EUROPE: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.3.5 EUROPE: IMPACT OF RECESSION
     10.4 ASIA PACIFIC 
             FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
             TABLE 117 ASIA PACIFIC: MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
             TABLE 118 ASIA PACIFIC: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
             TABLE 119 ASIA PACIFIC: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
             TABLE 120 ASIA PACIFIC: MARKET, BY APPLICATION,  2023–2029 (USD MILLION)
             TABLE 121 ASIA PACIFIC: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Increasing R&D investments to drive growth
                                      TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 123 CHINA: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 124 CHINA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 125 CHINA: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Growing geriatric population to present opportunities for market growth
                                      TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 127 JAPAN: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 128 JAPAN: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 129 JAPAN: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Increasing prevalence of chronic diseases to support growth
                                      TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                      TABLE 131 INDIA: MARKET, BY DISEASE, 2023–2029 (USD MILLION)
                                      TABLE 132 INDIA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                      TABLE 133 INDIA: MARKET, BY TYPE, 2023–2029 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT,  2023–2029 (USD MILLION)
                        TABLE 135 REST OF ASIA PACIFIC: MARKET, BY DISEASE,  2023–2029 (USD MILLION)
                        TABLE 136 REST OF ASIA PACIFIC: MARKET, BY APPLICATION,  2023–2029 (USD MILLION)
                        TABLE 137 REST OF ASIA PACIFIC: MARKET, BY TYPE,  2023–2029 (USD MILLION)
             10.4.5 ASIA PACIFIC: RECESSION IMPACT
     10.5 REST OF THE WORLD 
             TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT,  2023–2029 (USD MILLION)
             TABLE 139 REST OF THE WORLD: MARKET, BY DISEASE,  2023–2029 (USD MILLION)
             TABLE 140 REST OF THE WORLD: MARKET, BY APPLICATION,  2023–2029 (USD MILLION)
             TABLE 141 REST OF THE WORLD: MARKET, BY TYPE,  2023–2029 (USD MILLION)
             10.5.1 REST OF THE WORLD: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 134)
     11.1 INTRODUCTION 
     11.2 KEY STRATEGIES ADOPTED BY PLAYERS 
             FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 COMPANY EVALUATION QUADRANT 
             FIGURE 26 MARKET: COMPANY EVALUATION MATRIX (2022)
             11.3.1 STARS
             11.3.2 EMERGING LEADERS
             11.3.3 PERVASIVE PLAYERS
             11.3.4 PARTICIPANTS
     11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             11.4.1 PROGRESSIVE COMPANIES
             11.4.2 STARTING BLOCKS
             11.4.3 RESPONSIVE COMPANIES
             11.4.4 DYNAMIC COMPANIES
                        FIGURE 27 MARKET: START-UPS/SMES EVALUATION  QUADRANT (2022)
             11.4.5 COMPETITIVE BENCHMARKING
                        11.4.5.1 market: Detailed list of start-ups/SMEs
                                      TABLE 142 MARKET: DETAILED LIST OF START-UPS/SMES
                        11.4.5.2 market: Competitive benchmarking of key players (start-ups/SMEs)
                                      TABLE 143 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
     11.5 COMPETITIVE SCENARIO AND TRENDS 
             TABLE 144 MARKET: DEALS
             11.5.1 PRODUCT LAUNCHES
                        TABLE 145 MARKET: PRODUCT LAUNCHES
             11.5.2 EXPANSIONS
                        TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS
 
12 COMPANY PROFILES (Page No. - 145)
(Business overview, Products offered, Recent Developments, MNM view)*
     12.1 KEY PLAYERS 
             12.1.1 SERES THERAPEUTICS, INC.
                        TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW
             12.1.2 ENTEROME
                        TABLE 148 ENTEROME: COMPANY OVERVIEW
             12.1.3 4D PHARMA PLC
                        TABLE 149 4D PHARMA: COMPANY OVERVIEW
                        FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022)
             12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
                        TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
                        FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)
             12.1.5 OPTIBIOTIX HEALTH PLC
                        TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW
                        FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021)
             12.1.6 FERRING PHARMACEUTICALS
                        TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW
             12.1.7 SYNLOGIC, INC.
                        TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW
                        FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022)
             12.1.8 SECOND GENOME INC.
                        TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW
             12.1.9 VEDANTA BIOSCIENCES, INC.
                        TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW
             12.1.10 YSOPIA BIOSCIENCE
                        TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW
             12.1.11 FLIGHTPATH BIOSCIENCES, INC.
                        TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW
             12.1.12 FINCH THERAPEUTICS GROUP, INC.
                        TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW
                        FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)
             12.1.13 AOBIOME THERAPEUTICS
                        TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW
             12.1.14 BIOGAIA
                        TABLE 160 BIOGAIA: COMPANY OVERVIEW
                        FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021)
             12.1.15 QUANTBIOME, INC. (DBA OMBRE)
                        TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 VIOME LIFE SCIENCES, INC.
             12.2.2 BIOHM HEALTH
             12.2.3 DAYTWO
             12.2.4 ALTAS BIOMED
             12.2.5 BIONE VENTURES PRIVATE LIMITED
             12.2.6 LUXIA SCIENTIFIC
             12.2.7 METABIOMICS
             12.2.8 SUN GENOMICS
             12.2.9 SEED HEALTH
             12.2.10 GNUBIOTICS SCIENCES
 
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies. 
 
13 APPENDIX (Page No. - 183)
     13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.2 CUSTOMIZATION OPTIONS 
     13.3 RELATED REPORTS 
     13.4 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the human microbiome market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the human microbiome market. The secondary sources used for this study include some of the key secondary sources referred to for this study include publications from government sources such as World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Interviews with Experts, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Human Microbiome Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Alexander Puttick

PhD Researcher

Christophe C

CMC&Process development Biotech

Eugene Chang

Director

Mark Parker

Global Business Development

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the human microbiome market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the human microbiome business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Human microbiome Market: Bottom Up Approach

Human Microbiome Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Human microbiome Market Size: Top Down Approach

Human Microbiome Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The human microbiome refers to a collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that live within and on the human body. These microorganisms interact with each other and with the human host in a complex and dynamic manner, playing important roles in a range of physiological processes, including digestion, immune function, and metabolism. The human microbiome is highly diverse and varies between individuals and different regions of the body. The market encompasses various sectors, including research tools, diagnostics, therapeutics, and consumer products, aimed at leveraging the knowledge and potential of the microbiome to improve human health and well-being. This includes the development and commercialization of microbiome-based therapies, such as live biotherapeutic products (LBPs), probiotics, prebiotics, and other microbial interventions, as well as the development of diagnostic tools for assessing and monitoring the microbiome.

Key Stakeholders

  • Manufacturers and distributors of human microbiome products
  • Pharmaceutical and biotechnology companies
  • Market research and consulting firms
  • R&D centers
  • Researchers and scientists
  • Academic & research institutes

Report Objectives

  • To define, describe, and forecast the human microbiome market based on products, type, application, and disease.
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
  • To strategically analyse micro markets with respect to individual growth trends, future prospects, and contributions to the overall human microbiome market
  • To analyse opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the human microbiome market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Twenty five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 2711
Published ON
May, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Human Microbiome Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback